Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles

Csilla Bartos, Rita Ambrus, P. Sípos, Mária Budai-Szucs, Erzsébet Csányi, R. Gáspár, A. Márki, Adrienn B. Seres, Anita Sztojkov-Ivanov, Tamás Horváth, P. Szabó-Révész

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This article reports on the micro- and nanonization of meloxicam (MEL) with the aim of developing pre-dispersions as intermediates for the design of intranasal formulations. As a new approach, combined wet milling technology was developed in order to reduce the particle size of the MEL. Different milling times resulted in micro- or nanosized MEL in the pre-dispersions with polyvinyl alcohol as stabilizer agent, which were directly used for preparing intranasal liquid formulations with the addition of sodium hyaluronate as mucoadhesive agent. Reduction of the MEL particle size into the nano range led to increased saturation solubility and dissolution velocities, and increased adhesiveness to surfaces as compared with microsized MEL particles. A linear correlation was demonstrated between the specific surface area of MEL and the AUC. The in vitro and in vivo studies indicated that the longer residence time and the uniform distribution of nano MEL spray throughout an artificial membrane and the nasal mucosa resulted in better diffusion and a higher AUC. Nanosized MEL may be suggested for the development of an innovative dosage form with a different dose of the drug, as a possible administration route for pain management.

Original languageEnglish
Pages (from-to)198-207
Number of pages10
JournalInternational Journal of Pharmaceutics
Volume491
Issue number1-2
DOIs
Publication statusPublished - Jul 6 2015

Fingerprint

meloxicam
Hyaluronic Acid
Particle Size
Area Under Curve
Electronic Nose
Artificial Membranes
Polyvinyl Alcohol
Adhesiveness
Nasal Mucosa
Dosage Forms
Pain Management
Solubility

Keywords

  • AUC
  • Combined wet milling
  • Intranasal formulation
  • Meloxicam
  • Mucoadhesivity
  • Permeability

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles. / Bartos, Csilla; Ambrus, Rita; Sípos, P.; Budai-Szucs, Mária; Csányi, Erzsébet; Gáspár, R.; Márki, A.; Seres, Adrienn B.; Sztojkov-Ivanov, Anita; Horváth, Tamás; Szabó-Révész, P.

In: International Journal of Pharmaceutics, Vol. 491, No. 1-2, 06.07.2015, p. 198-207.

Research output: Contribution to journalArticle

Bartos, Csilla ; Ambrus, Rita ; Sípos, P. ; Budai-Szucs, Mária ; Csányi, Erzsébet ; Gáspár, R. ; Márki, A. ; Seres, Adrienn B. ; Sztojkov-Ivanov, Anita ; Horváth, Tamás ; Szabó-Révész, P. / Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles. In: International Journal of Pharmaceutics. 2015 ; Vol. 491, No. 1-2. pp. 198-207.
@article{11587995469f4e3f9ef2c0a7033fd5e5,
title = "Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles",
abstract = "This article reports on the micro- and nanonization of meloxicam (MEL) with the aim of developing pre-dispersions as intermediates for the design of intranasal formulations. As a new approach, combined wet milling technology was developed in order to reduce the particle size of the MEL. Different milling times resulted in micro- or nanosized MEL in the pre-dispersions with polyvinyl alcohol as stabilizer agent, which were directly used for preparing intranasal liquid formulations with the addition of sodium hyaluronate as mucoadhesive agent. Reduction of the MEL particle size into the nano range led to increased saturation solubility and dissolution velocities, and increased adhesiveness to surfaces as compared with microsized MEL particles. A linear correlation was demonstrated between the specific surface area of MEL and the AUC. The in vitro and in vivo studies indicated that the longer residence time and the uniform distribution of nano MEL spray throughout an artificial membrane and the nasal mucosa resulted in better diffusion and a higher AUC. Nanosized MEL may be suggested for the development of an innovative dosage form with a different dose of the drug, as a possible administration route for pain management.",
keywords = "AUC, Combined wet milling, Intranasal formulation, Meloxicam, Mucoadhesivity, Permeability",
author = "Csilla Bartos and Rita Ambrus and P. S{\'i}pos and M{\'a}ria Budai-Szucs and Erzs{\'e}bet Cs{\'a}nyi and R. G{\'a}sp{\'a}r and A. M{\'a}rki and Seres, {Adrienn B.} and Anita Sztojkov-Ivanov and Tam{\'a}s Horv{\'a}th and P. Szab{\'o}-R{\'e}v{\'e}sz",
year = "2015",
month = "7",
day = "6",
doi = "10.1016/j.ijpharm.2015.06.046",
language = "English",
volume = "491",
pages = "198--207",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles

AU - Bartos, Csilla

AU - Ambrus, Rita

AU - Sípos, P.

AU - Budai-Szucs, Mária

AU - Csányi, Erzsébet

AU - Gáspár, R.

AU - Márki, A.

AU - Seres, Adrienn B.

AU - Sztojkov-Ivanov, Anita

AU - Horváth, Tamás

AU - Szabó-Révész, P.

PY - 2015/7/6

Y1 - 2015/7/6

N2 - This article reports on the micro- and nanonization of meloxicam (MEL) with the aim of developing pre-dispersions as intermediates for the design of intranasal formulations. As a new approach, combined wet milling technology was developed in order to reduce the particle size of the MEL. Different milling times resulted in micro- or nanosized MEL in the pre-dispersions with polyvinyl alcohol as stabilizer agent, which were directly used for preparing intranasal liquid formulations with the addition of sodium hyaluronate as mucoadhesive agent. Reduction of the MEL particle size into the nano range led to increased saturation solubility and dissolution velocities, and increased adhesiveness to surfaces as compared with microsized MEL particles. A linear correlation was demonstrated between the specific surface area of MEL and the AUC. The in vitro and in vivo studies indicated that the longer residence time and the uniform distribution of nano MEL spray throughout an artificial membrane and the nasal mucosa resulted in better diffusion and a higher AUC. Nanosized MEL may be suggested for the development of an innovative dosage form with a different dose of the drug, as a possible administration route for pain management.

AB - This article reports on the micro- and nanonization of meloxicam (MEL) with the aim of developing pre-dispersions as intermediates for the design of intranasal formulations. As a new approach, combined wet milling technology was developed in order to reduce the particle size of the MEL. Different milling times resulted in micro- or nanosized MEL in the pre-dispersions with polyvinyl alcohol as stabilizer agent, which were directly used for preparing intranasal liquid formulations with the addition of sodium hyaluronate as mucoadhesive agent. Reduction of the MEL particle size into the nano range led to increased saturation solubility and dissolution velocities, and increased adhesiveness to surfaces as compared with microsized MEL particles. A linear correlation was demonstrated between the specific surface area of MEL and the AUC. The in vitro and in vivo studies indicated that the longer residence time and the uniform distribution of nano MEL spray throughout an artificial membrane and the nasal mucosa resulted in better diffusion and a higher AUC. Nanosized MEL may be suggested for the development of an innovative dosage form with a different dose of the drug, as a possible administration route for pain management.

KW - AUC

KW - Combined wet milling

KW - Intranasal formulation

KW - Meloxicam

KW - Mucoadhesivity

KW - Permeability

UR - http://www.scopus.com/inward/record.url?scp=84934766608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934766608&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2015.06.046

DO - 10.1016/j.ijpharm.2015.06.046

M3 - Article

C2 - 26142244

AN - SCOPUS:84934766608

VL - 491

SP - 198

EP - 207

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -